Product Description
Fludeoxyglucose F18 is a radioactive tracer that acts as a glucose analog and is used for diagnostic purposes in conjunction with positron-emitting tomography (PET) to localize the tissues with altered glucose metabolism. It does not have therapeutic use. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK557653/)
Mechanisms of Action: Imaging
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Belgium | Bulgaria | Canada | Estonia | Finland | France | Germany | Hungary | Ireland | Italy | Luxembourg | Netherlands | Norway | Portugal | Romania | Russia | Singapore | Sweden | Switzerland | Taiwan | Turkey | United States | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: EBG MedAustron
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Switzerland, United States
Active Clinical Trial Count: 4
Highest Development Phases
Phase 3: COVID-19|Multiple Myeloma
Phase 1: Adenocarcinoma|Adrenocortical Carcinoma|Breast Cancer|Cutaneous Squamous Cell Carcinoma|Glioma|Head and Neck Cancer|Lung Cancer|Neuroendocrine Carcinoma|Neuroendocrine Tumors|Pancreatic Cancer|Paraganglioma|Pheochromocytoma|Skin Cancer|Squamous Cell Carcinoma|Thyroid Cancer|Uveal Melanoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCI-2019-05764 | P1 |
Recruiting |
Pheochromocytoma|Pancreatic Cancer|Paraganglioma|Adrenocortical Carcinoma|Neuroendocrine Tumors|Lung Cancer|Breast Cancer|Neuroendocrine Carcinoma|Thyroid Cancer|Cutaneous Squamous Cell Carcinoma|Squamous Cell Carcinoma|Skin Cancer|Head and Neck Cancer|Adenocarcinoma|Uveal Melanoma |
2025-10-01 |
|
| NCT02666547 | P1 |
Recruiting |
Glioma |
2023-12-01 |
|
| TEPCOV | P3 |
Completed |
COVID-19 |
2023-08-01 |
|
| MYELOCHOL | P3 |
Active, not recruiting |
Multiple Myeloma |
2020-09-13 |